Cyclacel Pharmaceuticals (NASDAQ:BGMS) Shares Down 0.9% – Time to Sell?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS)’s stock price was down 0.9% during trading on Thursday . The company traded as low as $0.98 and last traded at $0.9809. Approximately 36,781 shares traded hands during trading, a decline of 79% from the average daily volume of 176,564 shares. The stock had previously closed at $0.9903.

Analysts Set New Price Targets

A number of analysts recently weighed in on BGMS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 19th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cyclacel Pharmaceuticals has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Stock Down 0.9%

The stock has a market capitalization of $4.81 million, a PE ratio of -0.01 and a beta of -0.45. The business’s fifty day moving average price is $1.35.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.